Qyuns Therapeutics Co., Ltd. will convene its 2026 annual general meeting at 10:00 a.m. on 29 May 2026 in Taizhou, Jiangsu. Shareholders will decide on 13 resolutions covering operational reports, profit allocation, auditor engagement, capital mandates and governance restructuring. Key items include:

• FY 2025 Review and Profit Allocation – Board and Supervisory Board reports, together with the audited FY 2025 consolidated statements, are submitted for approval. – A profit distribution plan for the year ended 31 December 2025 is up for shareholder endorsement.

• Board and Auditor Compensation – The 2026 remuneration scheme for directors and supervisors will be voted on. – Re-appointment of KPMG as external auditor until the next AGM, with the Board authorised to set audit fees.

• Capital Management Proposals – A change in use of proceeds from the company’s prior global offering. – General mandates authorising the Board to issue shares and to repurchase H shares.

• Governance Restructure – Dissolution of the Supervisory Committee and corresponding amendments to the Articles of Association and procedural rules for shareholder and Board meetings. The Board would handle all related filings and formalities.

• Equity Incentives – Adoption of the 2026 Share Incentive Scheme. – Establishment of the overall Scheme Mandate Limit and a specific Service Provider Sublimit, both conditional on prior approval of the incentive plan.

Shareholders recorded in the register may appoint proxies and must submit forms to the H-share registrar, Tricor Investor Services Limited, by 10:00 a.m. on 28 May 2026 (Hong Kong time). Attendance requires proof of identity; treasury shares, if any, will carry no voting rights.